### Lymphoma
- **10002:** A Phase I Study of Indenoisoquinoline LMP744 in Adults with Relapsed Solid Tumors and Lymphomas
- **10106:** A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed and Refractory Lymphomas (Expansion: DLBCL (including high-grade B-cell lymphoma and transformed DLBCL))
- **10014:** A Pilot Study of Alazolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
- **10145:** Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas
- **10299:** A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
- **9875:** Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
- **9924:** A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
- **10244:** Phase I Study of GSK525762 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas (Expansion: At least one pancreatic cancer cohort and possibly others)
- **9930:** A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
- **10089:** A Randomized Phase 2 Study of CDX-1127 (Varilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
- **10130:** A Phase I Study of Single Agent Tazemetostat in Subjects with Advanced Solid Tumors or B-Cell Lymphomas with Hepatic Dysfunction
- **10204:** Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
- **10126:** A Pilot Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma

### Various Non-Hodgkin lymphomas
- **10193:** Phase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

### T-cell lymphomas
- **9930:** A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

### B-cell lymphomas
- **10089:** A Randomized Phase 2 Study of CDX-1127 (Varilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas

### Non-Hodgkin lymphoma
- **10126:** A Pilot Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma
- **10130:** A Phase I Study of Single Agent Tazemetostat in Subjects with Advanced Solid Tumors or B-Cell Lymphomas with Hepatic Dysfunction

### Hodgkin lymphoma
- **10002:** A Phase I Study of Indenoisoquinoline LMP744 in Adults with Relapsed Solid Tumors and Lymphomas
- **10106:** A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed and Refractory Lymphomas (Expansion: DLBCL (including high-grade B-cell lymphoma and transformed DLBCL))
- **10014:** A Pilot Study of Alazolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
- **10145:** Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas
- **10299:** A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: May 17, 2019